CytomX Therapeutics, Inc. (CTMX) Cash Flow Statement
CytomX Therapeutics, Inc. (CTMX) generated -$82.4M of operating cash flow over the twelve months to 2026-06-30, spent $74000 on capital expenditure and had free cash flow of -$82.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTMXCytomX Therapeutics, Inc.Follow CTMX — free
—
Price chart with a free account
- Market cap
- 505.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -27.4 | -2.0 | 170.4 | -75.5 | -140.5 | 5.3 | -119.0 | -110.8 | -56.0 | -86.2 | -75.6 | -82.4 | |
| Capital expenditure | 1.6 | 2.2 | 1.6 | 3.8 | 3.5 | 2.3 | 1.6 | 1.7 | 0.8 | 0.3 | 0.2 | -0.1 | |
| Free cash flow | -29.0 | -4.2 | 168.8 | -79.3 | -144.0 | 3.0 | -120.6 | -112.5 | -56.9 | -86.5 | -75.8 | -82.5 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | |
| Stock-based compensation | 4.0 | 10.1 | 11.3 | 16.9 | 19.1 | 14.8 | 13.2 | 13.1 | 8.6 | 7.7 | 6.3 | — |
USD millions · SEC XBRL
CytomX Therapeutics, Inc. — questions
- What is CytomX Therapeutics, Inc.'s operating cash flow?
- -$82.4M over the twelve months to 2026-06-30.
- How much does CytomX Therapeutics, Inc. spend on capital expenditure?
- $74000 over the twelve months to 2026-06-30.
- What is CytomX Therapeutics, Inc.'s free cash flow?
- -$82.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from CytomX Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.